share_log

Barclays Maintains Equal-Weight on Chemours, Lowers Price Target to $30

Barclays Maintains Equal-Weight on Chemours, Lowers Price Target to $30

巴克萊維持Chemours的同等權重,將目標股價下調至30美元
Benzinga Real-time News ·  2022/09/27 06:41

Barclays analyst Michael Leithead maintains Chemours (NYSE:CC) with a Equal-Weight and lowers the price target from $46 to $30.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論